Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion in the Real Life Severe Asthma Patients
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY
Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• 18 -80 years
• Severe uncontrolled eosinophilic asthma by GINA (Global Initiative for Asthma) criteria
• Clinical indication of Dupilumab
Locations
Other Locations
Spain
Hospital de la Santa Creu i Sant Pau. Carrer Mas Casanovas 90.
RECRUITING
Barcelona
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2024-12
Participants
Target number of participants: 30
Related Therapeutic Areas
Sponsors
Leads: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau